In the latest trading session, 0.75 million Lexaria Bioscience Corp (NASDAQ:LEXX) shares changed hands as the company’s beta touched 0.95. With the company’s most recent per share price at $1.29 changed hands at -$0.18 or -12.07% at last look, the market valuation stands at $22.64M. LEXX’s current price is a discount, trading about -244.19% off its 52-week high of $4.44. The share price had its 52-week low at $1.15, which suggests the last value was 10.85% up since then. When we look at Lexaria Bioscience Corp’s average trading volume, we note the 10-day average is 71050.0 shares, with the 3-month average coming to 151.66K.
Analysts gave the Lexaria Bioscience Corp (LEXX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LEXX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Lexaria Bioscience Corp’s EPS for the current quarter is expected to be 0.
Lexaria Bioscience Corp (NASDAQ:LEXX) trade information
Instantly LEXX was in red as seen in intraday trades today. With action -9.15%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -38.57%, with the 5-day performance at -9.15% in the red. However, in the 30-day time frame, Lexaria Bioscience Corp (NASDAQ:LEXX) is -19.38% down. Looking at the short shares, we see there were 0.55 million shares sold at short interest cover period of 5.49 days.
Lexaria Bioscience Corp (LEXX) estimates and forecasts
Year-over-year growth is forecast to reach 28.16% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 137k. 2 analysts are of the opinion that Lexaria Bioscience Corp’s revenue for the current quarter will be 137k. The company’s revenue for the corresponding quarters a year ago was 145k and 84k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -5.52%. The estimates for the next quarter sales put growth at 63.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.61%. The 2025 estimates are for Lexaria Bioscience Corp earnings to decrease by -24.47%, but the outlook for the next 5-year period is at 6.84% per year.
Lexaria Bioscience Corp (NASDAQ:LEXX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.81% of Lexaria Bioscience Corp shares while 8.21% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 8.91%. There are 8.21% institutions holding the Lexaria Bioscience Corp stock share, with ARMISTICE CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 7.3619% of the shares, roughly 1.02 million LEXX shares worth $2.84 million.
INVENOMIC CAPITAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 3.7067% or 0.51 million shares worth $1.43 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Northern Lights Fd Tr II-Invenomic Fd and Vanguard Extended Market Index Fund. With 200.65 shares estimated at $0.27 million under it, the former controlled 0.25% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.15% of the shares, roughly 117.23 shares worth around $0.16 million.
